Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huazhi Rougan Granule with Dual Therapy for H. pylori and MASH
NCT07159412Not yet recruiting
- Sponsor
- Nanjing First Hospital
- Start
- Aug 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of huazhi rougan granule in Helicobacter pylori infection and Metabolic dysfunction-associated steatohepatitis (MASH) (2 arms), sponsored by Nanjing First Hospital. Primary endpoint: Helicobacter pylori eradication rate at 12 weeks. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
huazhi rougan granule
03
Conditions
Helicobacter pylori infectionMetabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT07159412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07159412.